ArticleScientific reports2026
Mechanism of action of Astragalus membranaceus for treating diabetic foot ulcers based on single-cell RNA sequencing data and network pharmacology.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diabetic foot ulcer is a severe complication of diabetes, characterized by impaired wound healing and immune dysregulation. Although Astragalus membranaceus (AM) has been widely used and reported to exert beneficial effects in diabetic complications, its underlying mechanisms of action in DFU remain incompletely understood. This study integrated single-cell RNA sequencing (scRNA-seq) data from a public bioinformatic cohort (GSE245703; 4 non-diabetic foot ulcer (NFU) and 5 diabetic foot ulcer (DFU) samples) with network pharmacology to explore potential molecular mechanisms by which AM may be involved in DFU pathology. scRNA-seq analysis identified ten major cell types within the DFU microenvironment and revealed significant macrophage heterogeneity. Network pharmacology identified 14 active compounds in AM and their predicted targets, some of which overlapped with macrophage-associated differentially expressed genes. Molecular docking suggested strong binding affinities between selected AM compounds and macrophage-associated hub genes. qPCR validation in a clinical cohort (6 NFU and 9 DFU patients) confirmed differential expression of several candidate hub genes overlapping with predicted AM targets. Collectively, these results provide a single-cell-resolved, systems-level framework that links AM components to macrophage-associated molecular processes in DFU, offering a hypothesis-generating basis for future functional and translational studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.